ClinicalTrials.gg
Status unknownNCT05486598Updated Aug 3, 2022

A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects

A Phase 1 interventional study of AL8326 tablets in Diet, High-Fat and Pharmacokinetics, sponsored by Advenchen Laboratories Nanjing Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-03.

Sponsored by Advenchen Laboratories Nanjing Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Main study objective: the pharmacokinetic effects of high-fat diet on AL8326 after oral administration of AL8326 tablets in Chinese healthy adult subjects.

Secondary study objectives: safety and tolerability of a single oral dose of AL8326 tablets in healthy subjects

Read the detailed description

This is a Phase IB Clinical Trial to Evaluate the Effect of High-fat Diet on Pharmacokinetics of AL8326 Tablets in Chinese Healthy Adult Subjects.

Sixteen healthy subjects were randomly divided into two sequence groups, a and B, and eight subjects in each sequence group were dosed according to either the fasting → postprandial or the postprandial → fasting sequence. The washout period was 14 days.

02

Conditions studied

  • Diet, High-Fat
  • Pharmacokinetics
03

In context

Lead sponsor

Advenchen Laboratories Nanjing Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female subjects aged 18 \~ 65 years (including both 18 and 65 years);
  2. Body weight ≥ 50 kg for men and ≥ 45 kg for women, with a in the range 19-26 kg / m\^2 (inclusive 19 and 26) (BMI = body weight (kg) / height2 (M2));
  3. No mental abnormalities, no history of cardiovascular, nervous, respiratory, digestive, urinary, endocrine and metabolic abnormalities;
  4. Previous history, physical examination, vital signs, blood routine, urine routine, blood biochemistry, coagulation routine, pregnancy test (female), hepatitis, , syphilis, 12 lead , chest X-ray and other tests in the screening period, the whole of the results must be within the normal range matched to age and gender, or meet the protocol regulations, or if outside the normal range is judged as "not (NCS) ";
  5. Those who agree to be abstinent or have taken effective non drug for the duration of the study and for at least 3 months after last study drug administration (for female subjects also required to be abstinent or have taken effective non drug contraception for two weeks prior to study entry);
  6. Subject is able to communicate well with investigator and understand and comply with all requirements of this study, understand and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Allergic constitution (allergy to two or more substances) or known allergy to the study drug or to the same drug;
  2. The screening period examination was abnormal and .
  3. Regular use of sedative, hypnotic, or other addictive drugs within 6 months before enrollment;
  4. Those with a history of substance abuse or a positive urine drug abuse screen within 12 months prior to enrollment;
  5. Those who smoked more than 5 cigarettes per day, or could not stop using any tobacco products during the trial;
  6. Regular drinkers with a positive alcohol insufflation test or within 6 months prior to enrollment, who consumed more than 3 units of alcohol per day, or more than 21 units per week (one bottle of 350 ml of beer with 120 ml of liquor or 30 ml of spirits as 1 drinking unit);
  7. Use of any prescription drug, Chinese herbal medicine within 4 weeks prior to enrollment, and / or use of any over-the-counter (OTC), food supplement (including vitamins, calcium tablets, etc.) within 2 weeks prior to first dose;
  8. Had participated in other clinical trials and taken study drugs within 3 months before enrollment;
  9. Having a blood donor (blood donation with ingredients) or blood loss of 400 ml, or having a blood transfusion within 3 months before enrollment; Blood donation (component containing blood donation) or blood loss of 200 ml within 1 month before enrollment (except physiological blood loss in females);
  10. History of significant illness or major surgery, trauma, 3 months prior to screening.
  11. Had gastrointestinal disease causing clinically significant symptoms such as nausea, vomiting, diarrhea, or malabsorption syndrome or a history of severe vomiting, diarrhea within the week prior to enrollment;
  12. Pregnant, lactating female subjects and reproductive age female subjects unable to provide on request;
  13. surface antigen positive, antibody positive, syphilis antibody positive, antibody positive persons;
  14. Special requirements for the diet (including lactose intolerance), inability to comply with the diet provided and respective prescribers;
  15. Subject denied discontinuation of any beverage or food containing methylxanthine, e.g., caffeine (coffee, tea, cola, chocolate, etc.), 48 hours prior to first dose until the end of study;
  16. Subject denied discontinuation of any beverage or food containing grapefruit 7 days prior to first dose until the end of the study;
  17. Intolerance to venipuncture for blood collection or poor vascular status;
  18. Subjects who, in the judgment of the investigator, were not suitable for participation in this study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    AL8326(Fasting)

    After screening, the subjects were randomly assigned to two sequence groups A and B. after fasting at least 10 hours overnight, they took al8326 tablets according to the requirements of two sequence groups A and B.

    Drug: AL8326 tablets

  • Experimental
    AL8326(Postprandial)

    After screening, the subjects were randomly assigned to two sequence groups A and B. after fasting at least 10 hours overnight, they took al8326 tablets according to the requirements of two sequence groups A and B.

    Drug: AL8326 tablets

Interventions

  • Sequence A group: on the 1st day, take a single dose of AL8326 tablets on an empty stomach. On the 15th day, take a single dose of AL8326 tablets after meals. Sequence B group: on the 1st day after meal, take a single dose of AL8326 tablets; on the 15th day, take a single dose of AL8326 tablets on an empty stomach.

    Also known as: AL8326

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Effect of high fat diet on the pharmacokinetics of al8326 after oral administration of AL8326 tablets in Chinese healthy adult subjects.

    Time frame: 120 hours after each dose

  2. AUC0-∞

    Effect of high fat diet on the pharmacokinetics of al8326 after oral administration of AL8326 tablets in Chinese healthy adult subjects.

    Time frame: 120 hours after each dose

  3. Cmax

    Effect of high fat diet on the pharmacokinetics of al8326 after oral administration of AL8326 tablets in Chinese healthy adult subjects.

    Time frame: 120 hours after each dose

Secondary outcomes

  1. Tmax

    Safety and tolerability of a single oral dose of AL8326 tablets in healthy subjects.

    Time frame: 120 hours after each dose

  2. T1/2

    Safety and tolerability of a single oral dose of AL8326 tablets in healthy subjects.

    Time frame: 120 hours after each dose

  3. Incidence of adverse events / serious adverse events as well as severity

    Safety and tolerability of a single oral dose of AL8326 tablets in healthy subjects.

    Time frame: Day 15 (± 1) after the last Administration

07

Study locations

1 of 1 sites recruiting
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Dec 2022, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2022
First posted
Aug 3, 2022
StartActual
Jun 21, 2022
Primary completionEst.
Dec 2022
CompletionEst.
Dec 2022
Last update
Aug 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05486598
Lead sponsor
Advenchen Laboratories Nanjing Ltd.
Responsible party
Sponsor
First posted
Aug 3, 2022
Start date
Jun 21, 2022
Primary completion
Dec 2022 (estimated)
Completion
Dec 2022 (estimated)
Last update
Aug 3, 2022

Study contacts

Yingyin Li
Contact
anne@advenchen.com.cn
+8657188683590
Huaqing He
Contact
huaqingh@advenchen.com.cn
+8615205140516
Yu Cao
principal investigator · The Affiliated Hospital of Qingdao University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aurora B/VEGFR/FGFR Inhibitor AL8326

Start the discussion